| Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response AC Rodrigues, PMS Perin, SG Purim, VN Silbiger, FDV Genvigir, ... International journal of molecular sciences 12 (9), 5815-5827, 2011 | 72 | 2011 |
| CYP3A5⁎ 3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia MAV Willrich, MH Hirata, FDV Genvigir, SS Arazi, IMM Rebecchi, ... Clinica chimica acta 398 (1-2), 15-20, 2008 | 67 | 2008 |
| Leptin receptor gene polymorphisms are associated with adiposity and metabolic alterations in Brazilian individuals R Oliveira, A Cerda, FDV Genvigir, MF Sampaio, D Armaganijan, ... Arquivos Brasileiros de endocrinologia & metabologia 57, 677-684, 2013 | 64 | 2013 |
| The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells AC Rodrigues, R Curi, FDV GEnVIGIR, MH Hirata, RDC Hirata Acta Pharmacologica Sinica 30 (7), 956-964, 2009 | 56 | 2009 |
| ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment IMM Rebecchi, AC Rodrigues, SS Arazi, FDV Genvigir, MAV Willrich, ... Biochemical pharmacology 77 (1), 66-75, 2009 | 51 | 2009 |
| Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response AC Rodrigues, B Sobrino, FDV Genvigir, MAV Willrich, SS Arazi, ... Clinica Chimica Acta 417, 8-11, 2013 | 41 | 2013 |
| Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells FDV Genvigir, AC Rodrigues, A Cerda, SS Arazi, MAV Willrich, R Oliveira, ... Pharmacogenomics 11 (9), 1235-1246, 2010 | 41 | 2010 |
| Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients FDV Genvigir, PC Salgado, CR Felipe, EYF Luo, C Alves, A Cerda, ... Pharmacogenetics and Genomics 26 (10), 462-472, 2016 | 40 | 2016 |
| Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin Á Cerda, FDV Genvigir, SS Arazi, MH Hirata, EL Dorea, MMS Bernik, ... Clinica chimica acta 411 (9-10), 631-637, 2010 | 37 | 2010 |
| Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium–Based Treatment in Brazilian Kidney Transplant Recipients FDV Genvigir, AM Nishikawa, CR Felipe, H Tedesco‐Silva Jr, N Oliveira, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (5 …, 2017 | 34 | 2017 |
| Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients EY Tamashiro, CR Felipe, FDV Genvigir, AC Rodrigues, AB Campos, ... Drug metabolism and personalized therapy 32 (2), 89-95, 2017 | 32 | 2017 |
| Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response SS Arazi, FDV Genvigir, MAV Willrich, MH Hirata, EL Dorea, M Bernik, ... Clinica Chimica Acta 393 (2), 119-124, 2008 | 29 | 2008 |
| Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals FDV Genvigir, SA Soares, MH Hirata, MAV Willrich, SS Arazi, ... Clinica chimica acta 389 (1-2), 79-86, 2008 | 28 | 2008 |
| Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients MAV Willrich, AC Rodrigues, A Cerda, FDV Genvigir, SS Arazi, EL Dorea, ... Clinica Chimica Acta 421, 157-163, 2013 | 21 | 2013 |
| Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women MH Issa, A Cerda, FDV Genvigir, SA Cavalli, MC Bertolami, AA Faludi, ... The Journal of Steroid Biochemistry and Molecular Biology 128 (3-5), 139-144, 2012 | 17 | 2012 |
| Atorvastatin and hormone therapy influence expression of ABCA1, APOA1 and SCARB1 in mononuclear cells from hypercholesterolemic postmenopausal women A Cerda, MH Issa, FDV Genvigir, CB Rohde, SA Cavalli, MC Bertolami, ... The Journal of Steroid Biochemistry and Molecular Biology 138, 403-409, 2013 | 14 | 2013 |
| CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy FDV Genvigir, AB Campos-Salazar, CR Felipe, H Tedesco-Silva Jr, ... Pharmacogenomics 21 (1), 7-21, 2020 | 13 | 2020 |
| Modulation of Adhesion Molecules by Cholesterol‐Lowering Therapy in Mononuclear Cells from Hypercholesterolemic Patients A Cerda, AC Rodrigues, C Alves, FDV Genvigir, CM Fajardo, EL Dorea, ... Cardiovascular therapeutics 33 (4), 168-176, 2015 | 13 | 2015 |
| Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin A Cerda, FDV Genvigir, MAV Willrich, SS Arazi, M Bernik, EL Dorea, ... Lipids in health and disease 10 (1), 1-11, 2011 | 13 | 2011 |
| Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression Á Cerda, FDV Genvigir, AC Rodrigues, MAV Willrich, EL Dorea, ... Journal of Atherosclerosis and Thrombosis 18 (8), 640-651, 2011 | 13 | 2011 |
